Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
1995-03-27
2001-04-10
Saunders, David (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S172100, C424S173100, C424S174100, C424S179100, C424S181100, C424S183100, C530S367000, C530S388200, C530S388220, C530S388700, C530S388800, C530S389600, C530S389700, C548S303700
Reexamination Certificate
active
06214974
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the field of molecular biology and therapeutics. More specifically, the present invention relates to a novel non-viral vector for the delivery of genetic information to cells.
2. Description of the Related Art
Currently, the most common mechanism for delivery of genetic material capable of affecting molecular properties of mammalian cells utilizes viral, primarily retroviral, vectors. However, this mode of genetic therapy or delivery is influenced by several deficiencies and potentially hazardous conditions. Although retroviral vectors have been more common, adenoviral vectors are now being studied and both have some potential. Unfortunately, a viral vector has many disadvantages. First, the target cells, e.g., human cells, must be capable of interacting with viruses through expression of a specific cell surface element which may not be expressed on the cells or tissue of interest for delivery of genetic information. Second, the genetic material must be integrated and expressed in the target, e.g., human cell, which requires that target cells be actively dividing, a condition hindering the efficiency and homogeneity of this delivery system. Even if successfully integrated, the gene may be transcriptionally silent by host cell mechanisms. Third, the size of the genetic information allowable in this system is limited and must be engineered with great precision to ensure biologic activity. Fourth, the replication defective viruses must be utilized for gene therapy applications to reduce the risk of recombination with endogenous viruses which may form new infectious agents. Replication defective viruses may reduce this hazard but do not eliminate it. Fifth, the replication defective viruses are by design not self-removing, requiring repetitive infection to achieve successful delivery of gene sequences to all cells.
The prior art is deficient in the absence of non-viral vectors. The present invention fulfills this longstanding need and desire in the art.
SUMMARY OF THE INVENTION
The present invention provides, inter alia, a novel non-viral system for delivery of genetic materials capable of modification of deleterious or undesirable phenotypic characteristics.
Thus, in one embodiment of the present invention there is provided a non-viral vector, comprising a cell binding component having a biotin-binding element conjugated to a biotinylated moiety.
In another embodiment of the present invention, there is provided a method of introducing genetic material inside a specific cell comprising the administration of the non-viral vector to a human, wherein said non-viral vector comprises a cell binding component having a biotin-binding element conjugated to a biotinylated moiety.
In yet another embodiment of the present invention, there is provided a method of delivering a cytotoxic moiety to a cell comprising the administration of the non-viral vector to a human.
Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.
REFERENCES:
patent: 4545985 (1985-10-01), Pastan
patent: 0251494 (1988-01-01), None
Vitetta et al., Tips, 1993, 14:148.*
Wilchek et al., Anal. Biochem., 1988, 171:1.*
Osband, Immunol. Today, 1990, 11:193.*
Chatterjee, Cancer Immunol. Immunother., 1994, 38:78.*
Zwierzina, Stem Cells, 1993, 11:144.*
Curti, Crit. Rev. Oncol. Hemalol., 1993, 14:29.*
Jain, Scientific Am., 1994, 271:58.*
Martinez, Cancer Surveys, 1(3):374, 1982.*
Pastan, Cell, 47: 641, 1986.*
Chen et. al, FEBS Letters, 338:167-169 (1994).
Donato Nicholas J.
Rosenblum Michael G.
Benjamin Aaron Adler
Research Development Foundation
Saunders David
LandOfFree
Avidin-biotin immunoconjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Avidin-biotin immunoconjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Avidin-biotin immunoconjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2487216